Debt-to-equity of Atara Biotherapeutics, Inc. from 30 Jun 2015 to 31 Dec 2025
- Taxonomy & unit
- ratio: x
- Description
- Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's debt by its shareholder equity.
- Summary
-
Atara Biotherapeutics, Inc. quarterly Debt-to-equity in x history and change rate from 30 Jun 2015 to 31 Dec 2025.
- Atara Biotherapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was -1.9x, a 19% increase year-over-year.
Debt-to-equity, Quarterly (x)
Debt-to-equity, YoY Quarterly Change (%)
Atara Biotherapeutics, Inc. Quarterly Debt-to-equity (x)
| Period | Value | YoY Chg | Change % | Date |
|---|---|---|---|---|
| Q4 2025 | -1.9x | +0.44x | +19% | 31 Dec 2025 |
| Q3 2025 | -2.06x | +2.87x | +58% | 30 Sep 2025 |
| Q2 2025 | -2.26x | +3.93x | +63% | 30 Jun 2025 |
| Q1 2025 | -2.22x | +21.5x | +91% | 31 Mar 2025 |
| Q4 2024 | -2.35x | -10.46x | -129% | 31 Dec 2024 |
| Q3 2024 | -4.94x | -11.45x | -176% | 30 Sep 2024 |
| Q2 2024 | -6.2x | -8.54x | -364% | 30 Jun 2024 |
| Q1 2024 | -23.71x | -25.05x | -1882% | 31 Mar 2024 |
| Q4 2023 | 8.12x | +7.13x | +725% | 31 Dec 2023 |
| Q3 2023 | 6.51x | +5.75x | +757% | 30 Sep 2023 |
| Q2 2023 | 2.35x | +1.71x | +270% | 30 Jun 2023 |
| Q1 2023 | 1.33x | +0.78x | +143% | 31 Mar 2023 |
| Q4 2022 | 0.98x | +0.54x | +122% | 31 Dec 2022 |
| Q3 2022 | 0.76x | +0.41x | +119% | 30 Sep 2022 |
| Q2 2022 | 0.63x | +0.35x | +127% | 30 Jun 2022 |
| Q1 2022 | 0.55x | +0.32x | +146% | 31 Mar 2022 |
| Q4 2021 | 0.44x | +0.26x | +137% | 31 Dec 2021 |
| Q3 2021 | 0.35x | +0.19x | +125% | 30 Sep 2021 |
| Q2 2021 | 0.28x | +0.13x | +81% | 30 Jun 2021 |
| Q1 2021 | 0.22x | +0.05x | +30% | 31 Mar 2021 |
| Q4 2020 | 0.19x | +0.03x | +16% | 31 Dec 2020 |
| Q3 2020 | 0.15x | -0x | -0.38% | 30 Sep 2020 |
| Q2 2020 | 0.15x | +0.02x | +11% | 30 Jun 2020 |
| Q1 2020 | 0.17x | +0.05x | +45% | 31 Mar 2020 |
| Q4 2019 | 0.16x | +0.06x | +57% | 31 Dec 2019 |
| Q3 2019 | 0.16x | +0.05x | +48% | 30 Sep 2019 |
| Q2 2019 | 0.14x | +0.03x | +29% | 30 Jun 2019 |
| Q1 2019 | 0.12x | +0x | +1.8% | 31 Mar 2019 |
| Q4 2018 | 0.1x | -0.01x | -10% | 31 Dec 2018 |
| Q3 2018 | 0.1x | +0.03x | +46% | 30 Sep 2018 |
| Q2 2018 | 0.11x | +0.05x | +89% | 30 Jun 2018 |
| Q1 2018 | 0.12x | +0.07x | +178% | 31 Mar 2018 |
| Q4 2017 | 0.11x | +0.07x | +188% | 31 Dec 2017 |
| Q3 2017 | 0.07x | +0.03x | +93% | 30 Sep 2017 |
| Q2 2017 | 0.06x | +0.03x | +96% | 30 Jun 2017 |
| Q1 2017 | 0.04x | +0.01x | +22% | 31 Mar 2017 |
| Q4 2016 | 0.04x | +0.01x | +19% | 31 Dec 2016 |
| Q3 2016 | 0.04x | +0x | +11% | 30 Sep 2016 |
| Q2 2016 | 0.03x | -0.02x | -45% | 30 Jun 2016 |
| Q1 2016 | 0.03x | 31 Mar 2016 | ||
| Q4 2015 | 0.03x | 31 Dec 2015 | ||
| Q3 2015 | 0.03x | 30 Sep 2015 | ||
| Q2 2015 | 0.05x | 30 Jun 2015 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.